Boston Scientific's Stock Tumbles 30% Amid Product Woes and Recall Fallout
Boston Scientific (BSX) has faced a challenging year, with its stock hitting a 52-week low. The company, valued at around $102.8 billion, recently saw shares drop by 30% over the past 12 months, trading near $65.26. Despite this, some analysts remain optimistic about its long-term prospects. The decline followed concerns over slowing growth in key areas, particularly U.S. electrophysiology and its Watchman device. On February 4, 2026, shares plunged 17.6% after reports of product issues, including a recall affecting 1.6 million pacemaker patients worldwide. Raymond James responded by downgrading BSX from Strong Buy to Outperform and cutting its price target from $97 to $88.
Yet, the company has shown strong financial performance in other areas. BSX reported nearly 20% revenue growth, with a PEG ratio of 0.64, and trades at about 18 times projected 2027 earnings. It also maintains a dominant position in the U.S. electrophysiology market, outperforming rivals Medtronic and Abbott through rapid innovation and strategic acquisitions.
Recent regulatory wins include FDA 510(k) clearance for the Asurys fluid management system. Additionally, the CHAMPION-AF trial met its primary goals for the Watchman device, offering a positive sign for future growth. While Raymond James cited decelerating trends as a reason for caution, firms like Evercore ISI, Bernstein, and Stifel kept Outperform or Buy ratings on the stock. Boston Scientific continues to balance setbacks with progress. The company's strong market position in electrophysiology and recent FDA approvals provide a foundation for recovery. However, investor confidence remains shaky after the stock's steep decline and ongoing product concerns.
